Brand names
Nilutamide is marketed under the brand name Nilandron in the United States and under the brand name Anandron elsewhere in the world such as in Australia, Canada, Europe, and Latin America. Availability
Nilutamide is or has been available in the United States, Canada, Australia, Europe, Latin America, Egypt, and Lebanon. In Europe, it is or has been available in Belgium, Croatia, the Czech Republic, Finland, France, the Netherlands, Norway, Poland, Portugal, Serbia, Sweden, Switzerland, and Yugoslavia. in Latin America, it is or has been available in Argentina, Brazil, and Mexico. Research
The combination of an estrogen and nilutamide as a form of combined androgen blockade for the treatment of prostate cancer has been studied in animals.Nilutamide has been studied in the treatment of advanced breast cancer. References
Further reading
Raynaud JP, Bonne C, Moguilewsky M, Lefebvre FA, Bélanger A, Labrie F (1984). "The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review". Prostate. 5 (3): 299–311. doi:10.1002/pros.2990050307. PMID 6374639. S2CID 85417869. Moguilewsky M, Bertagna C, Hucher M (1987). "Pharmacological and clinical studies of the antiandrogen Anandron". J. Steroid Biochem. 27 (4–6): 871–5. doi:10.1016/0022-4731(87)90162-2. PMID 3320565. Du Plessis DJ (1991). "Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review". Urology. 37 (2 Suppl): 20–4. doi:10.1016/0090-4295(91)80097-q. PMID 1992599. Creaven PJ, Pendyala L, Tremblay D (1991). "Pharmacokinetics and metabolism of nilutamide". Urology. 37 (2 Suppl): 13–9. doi:10.1016/0090-4295(91)80096-p. PMID 1992598. Harris MG, Coleman SG, Faulds D, Chrisp P (1993). "Nilutamide.
Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome. Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.Maralixibat was approved for medical use in the United States in September 2021. History
Maralixibat was granted orphan drug designations in 2013, and in 2020. Society and culture
Legal status
On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Livmarli, intended for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The applicant for this medicinal product is Mirum Pharmaceuticals International B.V.

Names
Maralixibat chloride is the international nonproprietary name (INN). References
External links
"Maralixibat". Drug Information Portal. U.S. National Library of Medicine. "Maralixibat chloride". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02160782 for "Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)" at ClinicalTrials.gov